Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
Rhea-AI Summary
Positive
- Revenue grew 3% year-over-year to $1.9 million
- Strong 38% growth in pediatric revenue
- 31% reduction in operating expenses ($1.8 million savings)
- CMS increased Aquadex reimbursement nearly four-fold to $1,639 per day
- Net loss improved from $3.8M to $3.0M year-over-year
- Company remains debt-free
Negative
- Gross margin declined to 56.0% from 64.1% year-over-year
- International sales declined
- Cash position of $2.6M is relatively low given quarterly burn rate
- Still operating at a significant loss ($3.1M operating loss in Q1)
News Market Reaction – NUWE
On the day this news was published, NUWE gained 0.91%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
First Quarter 2025 and Recent Business Highlights
Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and emerging outpatient opportunities in 2025.
- Revenue of
$1.9 million , a3% increase over the prior-year quarter. 4% growth in consumables utilization year-over-year.- Pediatric revenue grew
38% year-over-year. - Operating expense reduction of
$1.8 million , or31% , compared to the prior-year quarter. - Effective January 1, 2025, CMS reassigned Aquadex to a higher outpatient reimbursement level, increasing the facility fee nearly four-fold to
$1,639 per day. - Expanded outpatient opportunity pipeline, driven by favorable reimbursement and supportive clinical data.
"We are encouraged by the strategic progress we’re making in expanding access to Aquadex therapy, particularly as more hospitals explore outpatient use," said John Erb, Chairman of the Board and Interim Chief Executive Officer of Nuwellis. "With higher reimbursement rates now in effect and a growing base of clinical support, we believe we are well-positioned to expand adoption across both inpatient and outpatient environments in 2025."
First Quarter 2025 Financial Results
Revenue for the first quarter of 2025 was
Gross margin for the first quarter of 2025 was
Selling, general, and administrative (SG&A) expenses for the first quarter of 2025 were
Research and development (R&D) expenses were
Total operating expenses for the quarter were
Operating loss improved to
Net loss attributable to common shareholders was
As of March 31, 2025, Nuwellis had
Conference Call and Webcast Information
Nuwellis will host a conference call and webcast today at 9:00 AM ET to discuss its first quarter results and recent business developments.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, participants may dial 1-800-579-2543 (U.S.) or 1-785-424-1789 (International) and use conference ID: NUWEQ1. A replay will be available following the event.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a commercial-stage medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company’s focus is on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minnesota, with a wholly owned subsidiary in Ireland. For more information, visit ir.nuwellis.com or follow us on LinkedIn or X.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding future growth and market opportunities. Forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties that could cause actual results to differ materially. These risks are detailed in the Company's filings with the Securities and Exchange Commission. Nuwellis undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
Investors:
Louisa Smith
Gilmartin Group
ir@nuwellis.com
Media Contact:
Leah McMullen
Nuwellis
Director of Communications
Leah.mcmullen@nuwellis.com
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | ||||||||||||||||||||||||
| March 31, 2025 | December 31, 2024 | |||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||
| ASSETS | ||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||
| Cash and cash equivalents | $ | 2,557 | $ | 5,095 | ||||||||||||||||||||
| Accounts receivable | 1,540 | 1,727 | ||||||||||||||||||||||
| Inventories, net | 1,752 | 1,718 | ||||||||||||||||||||||
| Other current assets | 274 | 315 | ||||||||||||||||||||||
| Total current assets | 6,123 | 8,855 | ||||||||||||||||||||||
| Property, plant and equipment, net | 405 | 478 | ||||||||||||||||||||||
| Operating lease right-of-use asset | 457 | 510 | ||||||||||||||||||||||
| Other assets | 21 | 21 | ||||||||||||||||||||||
| TOTAL ASSETS | $ | 7,006 | $ | 9,864 | ||||||||||||||||||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Accounts payable and accrued liabilities | $ | 1,731 | $ | 1,640 | ||||||||||||||||||||
| Accrued compensation | 689 | 640 | ||||||||||||||||||||||
| Current portion of operating lease liability | 243 | 238 | ||||||||||||||||||||||
| Other current liabilities | 86 | 41 | ||||||||||||||||||||||
| Total current liabilities | 2,749 | 2,559 | ||||||||||||||||||||||
| Common stock warrant liability | 426 | 468 | ||||||||||||||||||||||
| Operating lease liability | 249 | 307 | ||||||||||||||||||||||
| Total liabilities | 3,424 | 3,334 | ||||||||||||||||||||||
| Commitments and contingencies | ||||||||||||||||||||||||
| Mezzanine Equity Series J Convertible Preferred Stock as of March 31, 2025 and December 31, 2024, par value | 4 | 2 | ||||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||||||
| Series A junior participating preferred stock as of March 31, 2025 and December 31, 2024, par value | — | — | ||||||||||||||||||||||
| Series F convertible preferred stock as of March 31, 2025 and December 31, 2024, par value | — | — | ||||||||||||||||||||||
| Preferred stock as of March 31, 2025 and December 31, 2024, par value | — | — | ||||||||||||||||||||||
| Common stock as of March 31, 2025 and December 31, 2024, par value 4,373,968 and 4,373,968, respectively | — | — | ||||||||||||||||||||||
| Additional paid‑in capital | 305,432 | 305,366 | ||||||||||||||||||||||
| Accumulated other comprehensive income: | ||||||||||||||||||||||||
| Foreign currency translation adjustment | (49 | ) | (47 | ) | ||||||||||||||||||||
| Accumulated deficit | (301,805 | ) | (298,791 | ) | ||||||||||||||||||||
| Total stockholders’ equity | 3,578 | 6,528 | ||||||||||||||||||||||
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | $ | 7,006 | $ | 9,864 | ||||||||||||||||||||
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts and weighted average shares outstanding) | |||||||||||||||||
| Three months ended March 31 | |||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| Net sales | $ | 1,904 | $ | 1,857 | |||||||||||||
| Cost of goods sold | 837 | 666 | |||||||||||||||
| Gross profit | 1,067 | 1,191 | |||||||||||||||
| Operating expenses: | |||||||||||||||||
| Selling, general and administrative | 3,577 | 4,606 | |||||||||||||||
| Research and development | 550 | 1,334 | |||||||||||||||
| Total operating expenses | 4,127 | 5,940 | |||||||||||||||
| Loss from operations | (3,060 | ) | (4,749 | ) | |||||||||||||
| Other income (expense), net | 7 | (101 | ) | ||||||||||||||
| Change in fair value of warrant liability | 40 | 522 | |||||||||||||||
| Loss before income taxes | (3,013 | ) | (4,328 | ) | |||||||||||||
| Income tax expense | (1 | ) | (2 | ) | |||||||||||||
| Net loss | (3,014 | ) | (4,330 | ) | |||||||||||||
| Deemed dividend attributable to Series J Convertible Preferred Stock | 1 | 541 | |||||||||||||||
| Net loss attributable to common shareholders | $ | (3,013 | ) | $ | (3,789 | ) | |||||||||||
| Basic and diluted loss per share | $ | (0.69 | ) | $ | (24.11 | ) | |||||||||||
| Weighted average shares outstanding – basic and diluted | 4,373,968 | 179,608 | |||||||||||||||
| Other comprehensive loss: | |||||||||||||||||
| Net loss | $ | (3,014 | ) | $ | (4,330) | ||||||||||||
| Foreign currency translation adjustments | (2 | ) | (9 | ) | |||||||||||||
| Total comprehensive loss | $ | (3,016 | ) | $ | (4,339 | ) | |||||||||||
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) | ||||||||||||||||||
| Three months ended March 31 | ||||||||||||||||||
| 2025 | 2024 | |||||||||||||||||
| Operating Activities: | ||||||||||||||||||
| Net loss | $ | (3,014 | ) | $ | (4,330 | ) | ||||||||||||
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||||||||||||||||||
| Depreciation and amortization | 73 | 76 | ||||||||||||||||
| Stock-based compensation expense | 67 | 158 | ||||||||||||||||
| Change in fair value of warrant liability | (40 | ) | (522 | ) | ||||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||||||
| Accounts receivable | 187 | 725 | ||||||||||||||||
| Inventory, net | (34) | (134 | ) | |||||||||||||||
| Other current assets | 41 | 21 | ||||||||||||||||
| Other assets and liabilities | 45 | (6 | ) | |||||||||||||||
| Accounts payable and accrued expenses | 139 | 1,150 | ||||||||||||||||
| Net cash used in operating activities | (2,536 | ) | (2,862 | ) | ||||||||||||||
| Investing Activities: | ||||||||||||||||||
| Purchases of property and equipment | — | (29 | ) | |||||||||||||||
| Net cash used in investing activities | — | | (29 | ) | ||||||||||||||
| Financing Activities: | ||||||||||||||||||
| Proceeds from the exercise of Series J Convertible Preferred Warrants | — | 500 | ||||||||||||||||
| Net cash provided by financing activities | — | | 500 | |||||||||||||||
| Effect of exchange rate changes on cash | (2 | ) | (9 | ) | ||||||||||||||
| Net decrease in cash and cash equivalents | (2,538 | ) | (2,400 | ) | ||||||||||||||
| Cash and cash equivalents - beginning of period | 5,095 | 3,800 | ||||||||||||||||
| Cash and cash equivalents – end of period | $ | 2,557 | $ | 1,400 | ||||||||||||||
| Supplemental cash flow information | ||||||||||||||||||
| Issuance of Series J Preferred Stock for exercise of Warrants | $ | — | $ | 1,857 | ||||||||||||||
| Issuance of Common Stock for conversion of Series J Preferred Stock | $ | — | $ | 1,535 | ||||||||||||||
| Deemed dividend on Series J Preferred Stock | $ | 1 | $ | 541 | ||||||||||||||
FAQ
What was Nuwellis (NUWE) revenue in Q1 2025?
How much did NUWE's pediatric revenue grow in Q1 2025?
What is the new CMS reimbursement rate for Nuwellis's Aquadex therapy?
What was Nuwellis's (NUWE) net loss per share in Q1 2025?
How much cash does Nuwellis (NUWE) have as of March 31, 2025?
